Abstract
Aims To determine if serum levels of serum amyloid A (SAA) predict death and end-stage renal disease in a cohort of people with diabetic kidney disease. Methods In a longitudinal cohort study of 135 participants with type 2 diabetes and diabetic kidney disease, serum samples were assayed for SAA. Censored time-to-event analyses in Cox-proportional hazard models were utilized to assess SAA as a predictor of the primary outcome of death and end-stage renal disease. Results Participants were 73% Mexican-American (99/135) and 55% men (75/135), with a mean ± SD age of 57 ± 7.5 years. At baseline, participants had hemoglobin A1c of 8.6 ± 2.3%, systolic blood pressure of 153 ± 27 mm Hg, body mass index of 31 ± 9 kg/m2, median urine-albumin-to-creatinine ratio of 1861 mg/g (interquartile range 720–3912 mg/g), and estimated glomerular filtration rate of 55.7 ± 22.3 ml/min/1.73 m2. Over a median duration of follow-up of 3.5 years, 44% (60/135) of participants experienced a primary outcome event. The hazards ratio for the primary outcome was 3.03 (95% CI 1.43–6.40, p = 0.003) in the highest (> 1.0 μg/ml) compared to the lowest (< 0.55 μg/ml) SAA tertile in a model adjusted for urine-albumin-to-creatinine ratio, estimated glomerular filtration rate, age, sex, and race/ethnicity. Addition of SAA as a covariate improved the model C-statistic (Δ c = 0.017). Conclusions In a longitudinal cohort study of participants with type 2 diabetes and DKD, higher levels of serum SAA predicted higher risk of death and ESRD. SAA is a promising targetable biomarker for DKD.
| Original language | English (US) |
|---|---|
| Pages (from-to) | 1467-1472 |
| Number of pages | 6 |
| Journal | Journal of Diabetes and its Complications |
| Volume | 30 |
| Issue number | 8 |
| DOIs | |
| State | Published - Nov 1 2016 |
| Externally published | Yes |
Fingerprint
Keywords
- Biomarkers
- Chronic kidney disease
- Diabetes
- Inflammation
- Risk-stratification
ASJC Scopus subject areas
- Internal Medicine
- Endocrinology, Diabetes and Metabolism
- Endocrinology
Cite this
Serum amyloid a and risk of death and end-stage renal disease in diabetic kidney disease. / Dieter, Brad P.; McPherson, Sterling M.; Afkarian, Maryam; de Boer, Ian H.; Mehrotra, Rajnish; Short, Robert; Barbosa-Leiker, Celestina; Alicic, Radica Z.; Meek, Rick L.; Tuttle, Katherine R.
In: Journal of Diabetes and its Complications, Vol. 30, No. 8, 01.11.2016, p. 1467-1472.Research output: Contribution to journal › Article
}
TY - JOUR
T1 - Serum amyloid a and risk of death and end-stage renal disease in diabetic kidney disease
AU - Dieter, Brad P.
AU - McPherson, Sterling M.
AU - Afkarian, Maryam
AU - de Boer, Ian H.
AU - Mehrotra, Rajnish
AU - Short, Robert
AU - Barbosa-Leiker, Celestina
AU - Alicic, Radica Z.
AU - Meek, Rick L.
AU - Tuttle, Katherine R.
PY - 2016/11/1
Y1 - 2016/11/1
N2 - Aims To determine if serum levels of serum amyloid A (SAA) predict death and end-stage renal disease in a cohort of people with diabetic kidney disease. Methods In a longitudinal cohort study of 135 participants with type 2 diabetes and diabetic kidney disease, serum samples were assayed for SAA. Censored time-to-event analyses in Cox-proportional hazard models were utilized to assess SAA as a predictor of the primary outcome of death and end-stage renal disease. Results Participants were 73% Mexican-American (99/135) and 55% men (75/135), with a mean ± SD age of 57 ± 7.5 years. At baseline, participants had hemoglobin A1c of 8.6 ± 2.3%, systolic blood pressure of 153 ± 27 mm Hg, body mass index of 31 ± 9 kg/m2, median urine-albumin-to-creatinine ratio of 1861 mg/g (interquartile range 720–3912 mg/g), and estimated glomerular filtration rate of 55.7 ± 22.3 ml/min/1.73 m2. Over a median duration of follow-up of 3.5 years, 44% (60/135) of participants experienced a primary outcome event. The hazards ratio for the primary outcome was 3.03 (95% CI 1.43–6.40, p = 0.003) in the highest (> 1.0 μg/ml) compared to the lowest (< 0.55 μg/ml) SAA tertile in a model adjusted for urine-albumin-to-creatinine ratio, estimated glomerular filtration rate, age, sex, and race/ethnicity. Addition of SAA as a covariate improved the model C-statistic (Δ c = 0.017). Conclusions In a longitudinal cohort study of participants with type 2 diabetes and DKD, higher levels of serum SAA predicted higher risk of death and ESRD. SAA is a promising targetable biomarker for DKD.
AB - Aims To determine if serum levels of serum amyloid A (SAA) predict death and end-stage renal disease in a cohort of people with diabetic kidney disease. Methods In a longitudinal cohort study of 135 participants with type 2 diabetes and diabetic kidney disease, serum samples were assayed for SAA. Censored time-to-event analyses in Cox-proportional hazard models were utilized to assess SAA as a predictor of the primary outcome of death and end-stage renal disease. Results Participants were 73% Mexican-American (99/135) and 55% men (75/135), with a mean ± SD age of 57 ± 7.5 years. At baseline, participants had hemoglobin A1c of 8.6 ± 2.3%, systolic blood pressure of 153 ± 27 mm Hg, body mass index of 31 ± 9 kg/m2, median urine-albumin-to-creatinine ratio of 1861 mg/g (interquartile range 720–3912 mg/g), and estimated glomerular filtration rate of 55.7 ± 22.3 ml/min/1.73 m2. Over a median duration of follow-up of 3.5 years, 44% (60/135) of participants experienced a primary outcome event. The hazards ratio for the primary outcome was 3.03 (95% CI 1.43–6.40, p = 0.003) in the highest (> 1.0 μg/ml) compared to the lowest (< 0.55 μg/ml) SAA tertile in a model adjusted for urine-albumin-to-creatinine ratio, estimated glomerular filtration rate, age, sex, and race/ethnicity. Addition of SAA as a covariate improved the model C-statistic (Δ c = 0.017). Conclusions In a longitudinal cohort study of participants with type 2 diabetes and DKD, higher levels of serum SAA predicted higher risk of death and ESRD. SAA is a promising targetable biomarker for DKD.
KW - Biomarkers
KW - Chronic kidney disease
KW - Diabetes
KW - Inflammation
KW - Risk-stratification
UR - http://www.scopus.com/inward/record.url?scp=84981717392&partnerID=8YFLogxK
UR - http://www.scopus.com/inward/citedby.url?scp=84981717392&partnerID=8YFLogxK
U2 - 10.1016/j.jdiacomp.2016.07.018
DO - 10.1016/j.jdiacomp.2016.07.018
M3 - Article
C2 - 27522272
AN - SCOPUS:84981717392
VL - 30
SP - 1467
EP - 1472
JO - Journal of Diabetes and its Complications
JF - Journal of Diabetes and its Complications
SN - 1056-8727
IS - 8
ER -